{
    "Project Title": "Evaluation of the sensitivity and specificity, compared to DLQI as a standard tool, of a novel QoL questionnaire (treat to the Patient satiSfactiOn TARGET in Psoriasis patients) among moderate to severe psoriasis patients treated with brodalumab (Kyntheum\u00ae)",
    "Sponsor": "LEO Pharma France",
    "Study Number": "2020-A00652-37",
    "Protocol Version and Date": "Version: 2.0, Date: 25-05-2020",
    "Study Title": "Evaluation of the sensitivity and specificity, compared to DLQI as a standard tool, of a novel QoL questionnaire (treat to the PSOriasis patient satiSfactiOn TARGET) among moderate to severe psoriasis patients treated with brodalumab (Kyntheum\u00ae)",
    "Phase": "Not Available",
    "Therapeutic Area": "Psoriasis",
    "Number of Patients": "150",
    "Number of Sites": "10",
    "Indication": "Psoriasis",
    "Duration of Treatment": "56 weeks",
    "Schedule of Assessments": "Section number not specified, needs to refer to a table.",
    "questionnaires": [
        {
            "longName": "Dermatology Life Quality Index",
            "shortName": "DLQI",
            "type": "PRO",
            "questionnaireTiming": [
                "Base-line Visit (Day 0)",
                "3 months Visit (week 12-16)",
                "12 months visit (week 48-56)"
            ]
        },
        {
            "longName": "Psoriasis Area and Severity Index",
            "shortName": "PASI",
            "type": "ClinRO",
            "questionnaireTiming": [
                "Base-line Visit (Day 0)",
                "3 months Visit (week 12-16)",
                "12 months visit (week 48-56)"
            ]
        },
        {
            "longName": "PSO-TARGET QoL Component Grid",
            "shortName": "PSO-TARGET",
            "type": "PRO",
            "questionnaireTiming": [
                "Base-line Visit (Day 0)",
                "3 months Visit (week 12-16)",
                "12 months visit (week 48-56)"
            ]
        }
    ]
}